Today: 20 May 2026
This Is Why Loblaw Stock Fell Even as Profit Rose
6 May 2026
2 mins read

This Is Why Loblaw Stock Fell Even as Profit Rose

Toronto, May 6, 2026, 16:03 (EDT)

  • Loblaw fell short of first-quarter revenue forecasts, with wary shoppers holding back.
  • Profit climbed. The company bumped up its dividend and signed off on a fresh buyback.
  • No Frills and Maxi, both discount banners, are still right at the heart of the growth story.

Loblaw Companies Limited shares slipped in Toronto after the retailer came up short on first-quarter revenue forecasts Wednesday, despite reporting a profit increase and sticking with its full-year earnings guidance. Revenue reached C$14.48 billion, missing the C$14.55 billion figure analysts were looking for, according to LSEG data via Reuters.

This revenue miss is drawing attention, with investors zeroed in on whether Canadian grocers can keep pushing sales higher without relying too much on price hikes—especially as shoppers keep choosing cheaper options. Food inflation, shipping costs tied to oil, and overall higher prices are still shaping spending habits. Reuters noted that the same wary consumer trend has surfaced at both Albertsons and Dollarama.

Loblaw didn’t miss across every metric. The Brampton, Ontario-based retailer reported a 4.2% climb in retail revenue, hitting C$14.48 billion. Food retail same-store sales improved 2.4%, while the drug retail side saw a 4.1% pickup in same-store sales. E-commerce did even better—up 20.3%. Same-store sales reflect results from shops open long enough for year-over-year comparison.

Net earnings available to common shareholders climbed to C$594 million, or 50 Canadian cents per diluted share, compared with C$503 million, or 42 cents, in the same period last year. Adjusted diluted earnings—which exclude certain items—advanced 10.6% to 52 Canadian cents per share.

Per Bank, the chief executive, put the spotlight on store growth and value for the quarter. Loblaw added five new hard-discount locations along with eight drug stores. According to Bank, the company’s emphasis on “opening new stores” and delivering “value” is striking a chord with Canadian shoppers. Loblaw

Loblaw’s stock dropped roughly 5% to C$59.99 in late Toronto trading, according to MarketScreener, with investors shrugging off the earnings beat and zeroing in on weaker sales.

Management maintained the customer base hasn’t cracked—just shifted. On the call, the bank pointed to ongoing “trading down,” with shoppers opting for cheaper chicken cuts and more ground beef instead of steak. Chief Financial Officer Richard Dufresne described the second quarter as seeing “a slight change, but not material.” Investing.com

Loblaw bumped its quarterly dividend up 10%, bringing it to roughly 15.5 Canadian cents per share, according to The Canadian Press. On the pharmacy side, prescription traffic lifted results—GLP-1 drugs like Ozempic stood out, as Bank pointed to a 40% year-over-year jump for that segment.

Loblaw has tacked on a fresh way to return capital. The company said it got the Toronto Stock Exchange’s green light for a normal course issuer bid—Canada’s term for buybacks—enabling the purchase of as many as 58.1 million common shares in the 12 months beginning May 8.

One development away from the grocery shelves: EQB Inc. and Loblaw got the green light from Ottawa for EQB’s buyout of PC Financial just a day ago. Both companies are eyeing a summer 2026 close. Loblaw’s anticipating about C$600 million in cash from the deal and related transactions.

The danger? Trade-down behavior could stick around longer than Loblaw anticipates. Should suppliers hit the company with higher costs—think freight, oil—Loblaw faces a decision: keep prices steady to maintain foot traffic, or raise them and risk unsettling shoppers who are already hesitant.

Loblaw says it can juggle both—driving traffic to its discount stores while boosting profits. But judging by Wednesday’s reaction in the stock, investors are clearly expecting more.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Celsius Stock Near 52-Week Low Before Q1 Earnings as PepsiCo Energy Bet Faces Test
Previous Story

Celsius Stock Near 52-Week Low Before Q1 Earnings as PepsiCo Energy Bet Faces Test

AppLovin Stock Drops After Q1 Earnings Beat as Wall Street Questions What Comes Next
Next Story

AppLovin Stock Drops After Q1 Earnings Beat as Wall Street Questions What Comes Next

Go toTop